JP2002543185A5 - - Google Patents

Download PDF

Info

Publication number
JP2002543185A5
JP2002543185A5 JP2000615389A JP2000615389A JP2002543185A5 JP 2002543185 A5 JP2002543185 A5 JP 2002543185A5 JP 2000615389 A JP2000615389 A JP 2000615389A JP 2000615389 A JP2000615389 A JP 2000615389A JP 2002543185 A5 JP2002543185 A5 JP 2002543185A5
Authority
JP
Japan
Prior art keywords
alkyl
group
phenyl
independently selected
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000615389A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002543185A (ja
JP3722700B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/011632 external-priority patent/WO2000066558A1/en
Publication of JP2002543185A publication Critical patent/JP2002543185A/ja
Publication of JP2002543185A5 publication Critical patent/JP2002543185A5/ja
Application granted granted Critical
Publication of JP3722700B2 publication Critical patent/JP3722700B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000615389A 1999-05-04 2000-05-01 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体 Expired - Lifetime JP3722700B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30522699A 1999-05-04 1999-05-04
US09/305,266 1999-05-04
PCT/US2000/011632 WO2000066558A1 (en) 1999-05-04 2000-05-01 Piperazine derivatives useful as ccr5 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005236161A Division JP2006052225A (ja) 1999-05-04 2005-08-16 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体

Publications (3)

Publication Number Publication Date
JP2002543185A JP2002543185A (ja) 2002-12-17
JP2002543185A5 true JP2002543185A5 (enExample) 2005-10-27
JP3722700B2 JP3722700B2 (ja) 2005-11-30

Family

ID=23179892

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000615389A Expired - Lifetime JP3722700B2 (ja) 1999-05-04 2000-05-01 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
JP2005236161A Withdrawn JP2006052225A (ja) 1999-05-04 2005-08-16 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005236161A Withdrawn JP2006052225A (ja) 1999-05-04 2005-08-16 Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体

Country Status (31)

Country Link
EP (2) EP1175401B1 (enExample)
JP (2) JP3722700B2 (enExample)
KR (1) KR100439358B1 (enExample)
AR (5) AR023823A1 (enExample)
AT (2) ATE299865T1 (enExample)
AU (2) AU780888B2 (enExample)
BR (1) BR0010304A (enExample)
CA (1) CA2371583C (enExample)
CH (1) CH1175401H9 (enExample)
CL (1) CL2008002737A1 (enExample)
CO (1) CO5170523A1 (enExample)
CZ (1) CZ20013940A3 (enExample)
DE (2) DE60045528D1 (enExample)
DK (1) DK1175401T3 (enExample)
EG (1) EG24136A (enExample)
ES (1) ES2244437T3 (enExample)
HK (1) HK1039930B (enExample)
HU (1) HUP0202867A3 (enExample)
IL (1) IL145741A0 (enExample)
MY (1) MY128367A (enExample)
NO (1) NO322045B1 (enExample)
PE (1) PE20010150A1 (enExample)
PL (1) PL203116B1 (enExample)
RU (1) RU2299206C9 (enExample)
SA (2) SA00210271B1 (enExample)
SI (1) SI1175401T1 (enExample)
SK (2) SK287418B6 (enExample)
TR (1) TR200103214T2 (enExample)
TW (1) TWI285200B (enExample)
WO (1) WO2000066558A1 (enExample)
ZA (1) ZA200108868B (enExample)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7825121B2 (en) 1999-05-04 2010-11-02 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
ATE418542T1 (de) 2001-03-29 2009-01-15 Schering Corp Als ccr5-antagonisten verwendbare aryloxim- piperazine
CZ20032636A3 (cs) 2001-03-29 2003-12-17 Schering Corporation Látky antagonizující CCR5
MXPA04005210A (es) * 2001-11-29 2004-08-19 Schering Corp Procedimiento para la preparacion de composiciones que tienen una cantidad incrementada de sales farmaceuticamente activas de rotameros.
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
JP4671091B2 (ja) * 2002-03-18 2011-04-13 東レ・ファインケミカル株式会社 １−置換−２−メチルピペラジンの製造方法
EP2141153A3 (en) 2002-03-29 2010-05-26 Schering Corporation Stereoselective alkylation of chiral 2-methyl-4 protected piperazines
WO2003084950A1 (en) * 2002-03-29 2003-10-16 Schering Corporation Synthesis of piperidine and piperazine compounds as ccr5 antagonists
EP1498125A4 (en) * 2002-04-24 2008-08-20 Takeda Pharmaceutical USE OF COMPOUNDS WITH CCR ANTAGONISM
JP2003335737A (ja) 2002-05-21 2003-11-28 Central Glass Co Ltd 光学活性（ｒ）−１−（４−トリフルオロメチルフェニル）エチルアミン
TW200504033A (en) * 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
WO2004054616A1 (ja) * 2002-12-13 2004-07-01 Ono Pharmaceutical Co., Ltd. ケモカイン受容体の強結合部位に結合するアンタゴニストおよびアゴニスト
PE20040769A1 (es) * 2002-12-18 2004-11-06 Schering Corp Derivados de piperidina utiles como antagonisas ccr5
CA2517888C (en) 2003-03-14 2012-05-01 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
JP4710606B2 (ja) 2003-04-18 2011-06-29 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
JPWO2004092136A1 (ja) * 2003-04-18 2006-07-06 小野薬品工業株式会社 含窒素複素環化合物およびその用途
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
JP2007505951A (ja) * 2003-06-13 2007-03-15 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとしてのキノリルアミド誘導体類
GB0313661D0 (en) * 2003-06-13 2003-07-16 Avecia Ltd Process
MXPA05013596A (es) 2003-06-30 2006-03-09 Schering Corp Antagonistas de hormona concentradora de melanina para el tratamiento de obesidad.
CN101798299A (zh) 2003-11-03 2010-08-11 先灵公司 用作趋化因子受体抑制剂的双六氢吡啶衍生物
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US7705153B2 (en) 2004-02-05 2010-04-27 Schering Corporation Bipiperdine derivatives useful as CCR3 antagonists
JP2007522160A (ja) 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー ケモカインｃｃｒ５受容体モジュレーター
BRPI0508140B1 (pt) 2004-03-05 2015-03-17 Nissan Chemical Ind Ltd Composto benzamida substituída por isoxazolina da fórmula (1); da fórmula (2) substituído por 3,5-bis (aril substituído); da fórmula (4) substituída por alquinibenzeno ou um sal do mesmo; "pesticida, agroquímico, inseticida, parasiticida contendo como ingrediente ativo um ou mais composto benzamida substituída por isoxazolina e sal do mesmo"
GEP20094680B (en) * 2004-04-13 2009-05-10 Incyte Corp Piperazinylpiperidine derivatives as chemokine receptor antagonists
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
GB0417804D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
JP4894518B2 (ja) * 2004-09-13 2012-03-14 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
WO2006071875A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
CN101133048A (zh) 2005-01-06 2008-02-27 先灵公司 哌嗪化合物的药用盐制备
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CA2598489A1 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
AU2006214380A1 (en) * 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
CN101146793A (zh) 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
AU2006214378A1 (en) * 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
MX2007010258A (es) * 2005-02-23 2007-09-11 Schering Corp Derivados de piperidinil piperazina utiles como inhibidores de receptores de quimiocina.
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JPWO2006129679A1 (ja) 2005-05-31 2009-01-08 小野薬品工業株式会社 スピロピペリジン化合物およびその医薬用途
ES2330788T3 (es) 2005-06-02 2009-12-15 F. Hoffmann-La Roche Ag Derivados de piperidin-4-il-amida y su uso como antagonistas del subtipo 5 del receptor sst.
US7665658B2 (en) 2005-06-07 2010-02-23 First Data Corporation Dynamic aggregation of payment transactions
AU2006303368B2 (en) 2005-10-19 2011-05-26 F. Hoffmann-La Roche Ag Non-Nucleoside Reverse Transcriptase Inhibitors
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
AR063656A1 (es) * 2005-11-30 2009-02-11 Schering Corp Composiciones que comprenden una combinacion de antagonistas de ccr5 y cxcr4
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CA2637565A1 (en) 2006-01-18 2007-07-26 Schering Corporation Cannibinoid receptor modulators
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007105637A1 (ja) 2006-03-10 2007-09-20 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
SI2013211T1 (sl) 2006-04-21 2012-07-31 Novartis Ag Purinski derivati za uporabo kot agonisti receptorja adenozina A A
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
CN101501002B (zh) 2006-08-16 2012-06-27 弗·哈夫曼-拉罗切有限公司 非核苷逆转录酶抑制剂
MX2009003185A (es) 2006-09-29 2009-04-03 Novartis Ag Pirazolopirimidinas como inhibidores de lipido cinasa pi3k.
AU2007332654B2 (en) 2006-12-13 2013-06-20 F. Hoffmann-La Roche Ag 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
PL2104535T3 (pl) 2007-01-10 2011-05-31 Irm Llc Związki i kompozycje jako inhibitory proteazy aktywujące kanały
AU2008225766B2 (en) * 2007-03-15 2012-06-07 Novartis Ag Organic compounds and their uses
KR20090127298A (ko) 2007-03-29 2009-12-10 에프. 호프만-라 로슈 아게 헤테로사이클릭 항바이러스 화합물
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
MX2010003621A (es) * 2007-10-01 2010-04-14 Hoffmann La Roche N-heterociclil biaril carboxamidas como antagonistas del receptor ccr.
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
EP2259772A2 (en) * 2008-02-29 2010-12-15 Schering Corporation Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009128947A1 (en) * 2008-04-17 2009-10-22 Concert Pharmaceuticals, Inc. Piperazine derivatives
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EA020548B1 (ru) 2008-12-19 2014-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Циклические пиримидин-4-карбоксамиды в качестве антагонистов рецептора ccr2, предназначенные для лечения воспаления, астмы и хозл
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
KR101721280B1 (ko) 2009-08-17 2017-03-29 인텔리카인, 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
IN2012DN01453A (enExample) 2009-08-20 2015-06-05 Novartis Ag
EP2490687A1 (en) 2009-10-22 2012-08-29 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
ME01908B (me) 2009-12-17 2014-12-20 Boehringer Ingelheim Int Novi antagonisti ccr2 receptora i njihova primjena
JP5658272B2 (ja) * 2009-12-17 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２の新規アンタゴニスト及びこれらの使用
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
WO2011147772A1 (en) 2010-05-25 2011-12-01 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
PL2593452T3 (pl) 2010-07-14 2017-07-31 Novartis Ag Związki heterocykliczne będące agonistami receptora IP
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US9127000B2 (en) 2011-02-23 2015-09-08 Intellikine, LLC. Heterocyclic compounds and uses thereof
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
US20140271680A1 (en) 2011-08-12 2014-09-18 Universite Paris-Est Creteil Val De Marne Methods and pharmaceutical compositions for treatment of pulmonary hypertension
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
EP2755976B1 (en) 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2793893A4 (en) 2011-11-23 2015-07-08 Intellikine Llc IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
CN104169282B (zh) 2012-01-13 2016-04-20 诺华股份有限公司 Ip受体激动剂的盐
US20140357641A1 (en) 2012-01-13 2014-12-04 Novartis Ag IP receptor agonist heterocyclic compounds
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US20150005311A1 (en) 2012-01-13 2015-01-01 Novartis Ag IP receptor agonist heterocyclic compounds
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN110507654A (zh) 2012-04-03 2019-11-29 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP2015536940A (ja) 2012-10-29 2015-12-24 シプラ・リミテッド 抗ウイルス性ホスホネート類似体及びその製造方法
US9604981B2 (en) 2013-02-13 2017-03-28 Novartis Ag IP receptor agonist heterocyclic compounds
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
US10112926B2 (en) 2014-04-24 2018-10-30 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
EA033571B1 (ru) 2014-04-24 2019-11-06 Novartis Ag Производные пиразина в качестве ингибиторов фосфатидилинозитол 3-киназы
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
CN107108581B (zh) * 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
AU2016287584B2 (en) 2015-07-02 2020-03-26 Centrexion Therapeutics Corporation (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4yl)methanone citrate
MX2021015133A (es) 2019-06-10 2022-01-24 Novartis Ag Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia.
PE20220346A1 (es) 2019-08-28 2022-03-14 Novartis Ag Derivados de 1,3-fenil heteroarilo sustituidos y su uso en el tratamiento de enfermedades
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
SE9201956D0 (sv) * 1992-06-25 1992-06-25 Kabi Pharmacia Ab Novel nicotinicacid esters
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
EP1003514A4 (en) * 1997-07-25 2000-10-11 Merck & Co Inc CYCLIC AMINE MODULATORS OF CHEMOKIN RECEPTORS
CN1146559C (zh) * 1998-06-30 2004-04-21 先灵公司 毒蕈碱性拮抗剂

Similar Documents

Publication Publication Date Title
JP2002543185A5 (enExample)
RU2001132635A (ru) Производные пиперидина, применимые в качестве антагонистов сс R5
RU2375363C2 (ru) Пирролотриазиновые производные анилина, полезные в качестве ингибиторов киназы
RU2001132632A (ru) Производные пиперазина, применимые в качестве антагонистов CCR5
JP2001526222A5 (enExample)
JP2006512339A5 (enExample)
JP2009536660A5 (enExample)
AR057873A2 (es) Compuestos derivados de piperizina utiles como antagonistas ccr5, composiciones farmaceuticas que los comprenden, y el uso de los mismos para la preparacion de medicamentos
JP2005500311A5 (enExample)
JP2005519932A5 (enExample)
JP2005511698A5 (enExample)
GB9900334D0 (en) Tricylic vascular damaging agents
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2004517099A5 (enExample)
JP2006507220A5 (enExample)
RU2003131879A (ru) Антагонисты ccr5, полезные для лечения спид
JP2002543114A5 (enExample)
YU73502A (sh) Farmaceutski aktivni derivati pirolidina
JP2003513066A5 (enExample)
WO2005000840A8 (en) Substituted diketopiperazines and their use as oxytocin antagonists
JP2003509494A5 (enExample)
JP2006503056A5 (enExample)
JP2008542386A5 (enExample)
JP2007509052A5 (enExample)
WO2001083457A3 (en) Benzimidazole-2-carbamates and their use in cancer treatment